Blood-Based Test Predicts What Drugs May Work Best
Dr. Kenneth Yu is testing a blood-based assay that looks at which types of chemotherapies will work best for each pancreatic cancer patient.
RNA Precision Trial for Pancreatic Cancer Opens At Columbia
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
A Look at MEK and Autophagy Inhibition
Dr. Conan Kinsey looks at the MEK pathway as way to make immunotherapy more effective for pancreatic cancer patients.
A Year in Review: 2020
Although COVID-19 dominated the news, important new research and clinical trials began for pancreatic cancer patients.
Multi-Site Precision Promise Study Opens
Dr. Vincent Picozzi explains how Precision Promise clinical trial will use a personalized approach for pancreatic cancer patients.
Shedding More Light On Neoadjuvant Treatment
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
PATHFINDER Blood Test Trial Focused on Early Detection
Dr. Minetta Liu is part of the team conducting a clinical trial to find biomarkers that will become an easy blood test for pancreatic cancer.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.